Tricaprilin Phase 2 Pilot Study in Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

February 7, 2022

Study Completion Date

February 7, 2022

Conditions
Migraine
Interventions
DRUG

Tricaprilin

"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"

DRUG

Placebo

Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.

Trial Locations (10)

2010

Holdsworth House, Sydney

2259

Paratus Clinical Central Coast, Kanwal

Unknown

Calvary Adelaide Hospital, Adelaide

Paratus Clinical Research Western Sydney, Blacktown

Paratus Clinical Research Brisbane, Brisbane

Emeritus Research, Camberwell

Paratus Clinical Research Canberra, Canberra

Austin Health Hospital, Heidelberg

Alfred Health Hospital, Melbourne

Gold Coast University Hospital, Southport

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cerecin

INDUSTRY

NCT04437199 - Tricaprilin Phase 2 Pilot Study in Migraine | Biotech Hunter | Biotech Hunter